Exosens Share: The optronic company rises among the strongest gainers of the SBF 120
The Bordeaux-based optronic company rebounds this Wednesday, against the trend of a declining Paris market. The movement erases a significant portion of Tuesday's decline and occurs as the stock has settled below its moving averages.
A rebound that places Exosens among the top performers of a declining SBF 120
Exosens share gains 2.29% to €57.95 during the session, while the SBF 120 falls 0.34% and the CAC 40 declines 0.38%. The stock ranks among the strongest gainers of the index, far behind Forvia, but well above a hesitant market. This rebound follows the 3% decline recorded on Tuesday, which had brought the price back towards its long-term moving averages.
In terms of performance, the stock remains down 3.66% over one week, but still shows an advance of 35.24% over one year. The trading session context remains marked by tension on rates: the 10-year OAT stands at 4.72% according to the latest reading from the Banque de France on October 6, with a spread of 1.27 points versus the Bund.
The price remains below its moving averages, with support at €54.15
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Despite today's increase, Exosens share remains below its MA20 (€58.78, variance of 1.41%), its MA50 (€59.86) and its MA200 (€59.85), the latter standing 3.17% above the current price. A return above the €59.85 to €59.86 zone therefore remains to be confirmed, these two averages being virtually identical. The RSI at 43 remains neutral and the MACD, slightly negative, does not show marked momentum.
Support at €54.15 and resistance at €63.40 frame the current trading zone. The optronic company's next financial event is the publication of its nine-month revenue, expected on October 27.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
